Long-Term Safety Study of KW-6002 (Istradefylline) in the Treatment of Parkinson's Disease (Phase 3).

Trial Profile

Long-Term Safety Study of KW-6002 (Istradefylline) in the Treatment of Parkinson's Disease (Phase 3).

Completed
Phase of Trial: Phase III

Latest Information Update: 06 Feb 2017

At a glance

  • Drugs Istradefylline (Primary)
  • Indications Parkinson's disease
  • Focus Adverse reactions; Registrational
  • Sponsors Kyowa Hakko Kirin
  • Most Recent Events

    • 25 Mar 2013 Istradefylline has been approved in Japan according to a media release from Kyowa Hakko Kirin.
    • 24 May 2012 Actual patient number 308 added as reported by ClinicalTrials.gov.
    • 24 May 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top